Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Bolsters Pipeline With Avila Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila’s lead compound as well as other compounds to emerge from its technology platform.

Advertisement

Related Content

Janssen Tabs Start-Up Scholar Rock For New Immunology Approach
For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
People In The News: Tracking The Latest Industry Personnel Changes
Disease Foundations Are Finding Their Way In New Research Relationships
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
Avila/Clovis Partnership Moves To The Clinic
Celgene Flexes Its Muscles
Sanofi Bulks Up Oncology Development With Avila Collaboration
Avila Therapeutics Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel